Vicore Pharma Holding AB Sponsored ADR Statistics
Vicore Pharma Holding AB Sponsored ADR (VCRE) Stock Statistics & Valuation Metrics
Total Valuation
Vicore Pharma Holding AB Sponsored ADR has a market cap or net worth of $284.42M. The enterprise value is $190.38M.
- Market Cap
- $284.42M
- Enterprise Value
- $190.38M
Share Statistics
Vicore Pharma Holding AB Sponsored ADR has 28,164,452 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 28,164,452
- Owned by Insiders
- ―
- Owned by Institutions
- 4.20%
Financial Efficiency
Vicore Pharma Holding AB Sponsored ADR’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -41.31%.
- Return on Equity (ROE)
- -0.44
- Return on Assets (ROA)
- -0.39
- Return on Invested Capital (ROIC)
- -41.31%
- Return on Capital Employed (ROCE)
- -0.41
- Revenue Per Employee
- 103.16K
- Profits Per Employee
- -12.90M
- Employee Count
- 37
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Vicore Pharma Holding AB Sponsored ADR is -5.47. Vicore Pharma Holding AB Sponsored ADR’s PEG ratio is -0.35.
- PE Ratio
- -5.47
- PS Ratio
- 756.35
- PB Ratio
- 4.00
- Price to FCF
- -8.60
- Price to Operating Cash Flow
- -5.90
- PEG Ratio
- -0.35
Income Statement
In the last 12 months, Vicore Pharma Holding AB Sponsored ADR had revenue of 3.82M and earned -477.47M in profits. Earnings per share was -2.20.
- Revenue
- 3.82M
- Gross Profit
- 3.82M
- Operating Income
- -454.44M
- Pretax Income
- -477.47M
- Net Income
- -477.47M
- EBITDA
- -477.41M
- Earnings Per Share (EPS)
- -2.20
Cash Flow
In the last 12 months, operating cash flow was -352.67M and capital expenditures 0, giving a free cash flow of -352.67M billion.
- Operating Cash Flow
- -352.67M
- Free Cash Flow
- -352.67M
- Free Cash Flow per Share
- -11.92
Dividends & Yields
Vicore Pharma Holding AB Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.63%
- Earnings Yield
- -17.66%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- -26.47%
- 50-Day Moving Average
- 9.91
- 200-Day Moving Average
- 10.98
- Relative Strength Index (RSI)
- 50.18
- Average Volume (3m)
- 23.28K
Important Dates
Vicore Pharma Holding AB Sponsored ADR upcoming earnings date is Feb 25, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Vicore Pharma Holding AB Sponsored ADR as a current ratio of 10.28, with Debt / Equity ratio of 0.00%
- Current Ratio
- 10.28
- Quick Ratio
- 10.28
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.21
- Interest Coverage Ratio
- -7574.08
Taxes
In the past 12 months, Vicore Pharma Holding AB Sponsored ADR has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Vicore Pharma Holding AB Sponsored ADR EV to EBITDA ratio is -4.42, with an EV/FCF ratio of -7.43.
- EV to Sales
- 652.93
- EV to EBITDA
- -4.42
- EV to Free Cash Flow
- -7.43
- EV to Operating Cash Flow
- -5.07
Balance Sheet
Vicore Pharma Holding AB Sponsored ADR has $771.99M in cash and marketable securities with $0.00 in debt, giving a net cash position of $771.99M billion.
- Cash & Marketable Securities
- $771.99M
- Total Debt
- $0.00
- Net Cash
- $771.99M
- Net Cash Per Share
- $27.41
- Tangible Book Value Per Share
- $25.68
Margins
Gross margin is 100.00%, with operating margin of -14161.60%, and net profit margin of -13397.10%.
- Gross Margin
- 100.00%
- Operating Margin
- -14161.60%
- Pretax Margin
- -13390.33%
- Net Profit Margin
- -13397.10%
- EBITDA Margin
- -14756.35%
- EBIT Margin
- -14756.35%
Analyst Forecast
The average price target for Vicore Pharma Holding AB Sponsored ADR is $25.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $25.00
- Price Target Upside
- 152.53% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -50.05%
- EPS Growth Forecast
- -9.20%
Scores
- Smart Score
- 6
- AI Score
- ―

